IL1RAP Antibody Shows Early Responses in MDS and AML Cohorts

Previously missed November 4 issuer disclosure of ASH-abstract data: in an investigator-initiated Phase 1b/2a trial of nadunolimab, seven of ten evaluable higher-risk MDS patients responded on azacitidine combination, and three of nine adverse-risk relapsed




